These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 23543215)

  • 1. FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs.
    White AL; Chan HT; French RR; Beers SA; Cragg MS; Johnson PW; Glennie MJ
    Cancer Immunol Immunother; 2013 May; 62(5):941-8. PubMed ID: 23543215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody.
    White AL; Chan HT; Roghanian A; French RR; Mockridge CI; Tutt AL; Dixon SV; Ajona D; Verbeek JS; Al-Shamkhani A; Cragg MS; Beers SA; Glennie MJ
    J Immunol; 2011 Aug; 187(4):1754-63. PubMed ID: 21742972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fcγ receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization.
    White AL; Dou L; Chan HT; Field VL; Mockridge CI; Moss K; Williams EL; Booth SG; French RR; Potter EA; Butts C; Al-Shamkhani A; Cragg MS; Verbeek JS; Johnson PW; Glennie MJ; Beers SA
    J Immunol; 2014 Aug; 193(4):1828-35. PubMed ID: 25024386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies.
    Li F; Ravetch JV
    Science; 2011 Aug; 333(6045):1030-4. PubMed ID: 21852502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer.
    Richman LP; Vonderheide RH
    Cancer Immunol Res; 2014 Jan; 2(1):19-26. PubMed ID: 24416732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement.
    Dahan R; Barnhart BC; Li F; Yamniuk AP; Korman AJ; Ravetch JV
    Cancer Cell; 2016 Jun; 29(6):820-831. PubMed ID: 27265505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
    Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Vijh S; Johnson S; Bonvini E; Koenig S
    Cancer Res; 2007 Sep; 67(18):8882-90. PubMed ID: 17875730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy.
    Hamaguchi Y; Xiu Y; Komura K; Nimmerjahn F; Tedder TF
    J Exp Med; 2006 Mar; 203(3):743-53. PubMed ID: 16520392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy targeting inhibitory Fcγ receptor IIB (CD32b) in the mouse is limited by monoclonal antibody consumption and receptor internalization.
    Williams EL; Tutt AL; Beers SA; French RR; Chan CH; Cox KL; Roghanian A; Penfold CA; Butts CL; Boross P; Verbeek JS; Cragg MS; Glennie MJ
    J Immunol; 2013 Oct; 191(8):4130-40. PubMed ID: 24026082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcγ receptor engagement.
    Li F; Ravetch JV
    Proc Natl Acad Sci U S A; 2012 Jul; 109(27):10966-71. PubMed ID: 22723355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody.
    Zhang D; Goldberg MV; Chiu ML
    J Biol Chem; 2016 Dec; 291(53):27134-27146. PubMed ID: 27856634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutation of the TGN1412 anti-CD28 monoclonal antibody lower hinge confers specific FcγRIIb binding and retention of super-agonist activity.
    Chenoweth AM; Esparon S; Wines BD; Schuurman J; Labrijn AF; Hogarth PM
    Immunol Cell Biol; 2023 Aug; 101(7):657-662. PubMed ID: 36997299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activities of agonistic anti-TNFR antibodies require differential FcγRIIB coengagement in vivo.
    Li F; Ravetch JV
    Proc Natl Acad Sci U S A; 2013 Nov; 110(48):19501-6. PubMed ID: 24218606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells.
    Wilson NS; Yang B; Yang A; Loeser S; Marsters S; Lawrence D; Li Y; Pitti R; Totpal K; Yee S; Ross S; Vernes JM; Lu Y; Adams C; Offringa R; Kelley B; Hymowitz S; Daniel D; Meng G; Ashkenazi A
    Cancer Cell; 2011 Jan; 19(1):101-13. PubMed ID: 21251615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Galactosylation of IgG1 modulates FcγRIIB-mediated inhibition of murine autoimmune hemolytic anemia.
    Yamada K; Ito K; Furukawa J; Nakata J; Alvarez M; Verbeek JS; Shinohara Y; Izui S
    J Autoimmun; 2013 Dec; 47():104-10. PubMed ID: 24055197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FcγRIIB as a key determinant of agonistic antibody efficacy.
    White AL; Beers SA; Cragg MS
    Curr Top Microbiol Immunol; 2014; 382():355-72. PubMed ID: 25116108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Harnessing the immune system via FcγR function in immune therapy: a pathway to next-gen mAbs.
    Chenoweth AM; Wines BD; Anania JC; Mark Hogarth P
    Immunol Cell Biol; 2020 Apr; 98(4):287-304. PubMed ID: 32157732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human immunoglobulin G hinge regulates agonistic anti-CD40 immunostimulatory and antitumour activities through biophysical flexibility.
    Liu X; Zhao Y; Shi H; Zhang Y; Yin X; Liu M; Zhang H; He Y; Lu B; Jin T; Li F
    Nat Commun; 2019 Sep; 10(1):4206. PubMed ID: 31562320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-FcγRIIB mAb suppresses murine IgG-dependent anaphylaxis by Fc domain targeting of FcγRIII.
    Clay CD; Strait RT; Mahler A; Khodoun MV; Finkelman FD
    J Allergy Clin Immunol; 2018 Apr; 141(4):1373-1381.e5. PubMed ID: 28624610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fc glycoengineering of a PD-L1 antibody harnesses Fcγ receptors for increased antitumor efficacy.
    Cohen Saban N; Yalin A; Landsberger T; Salomon R; Alva A; Feferman T; Amit I; Dahan R
    Sci Immunol; 2023 Mar; 8(81):eadd8005. PubMed ID: 36867679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.